Peptide therapy for Type I diabetes: the immunological homunculus and the rationale for vaccination

[1]  I. Cohen.  Tending Adam's Garden: Evolving the Cognitive Immune Self , 2004 .

[2]  I. Cohen,et al.  The mycobacterial 65 kD heat-shock protein and autoimmune arthritis , 2004, Rheumatology International.

[3]  H. Kolb,et al.  The Receptor for Heat Shock Protein 60 on Macrophages Is Saturable, Specific, and Distinct from Receptors for Other Heat Shock Proteins1 , 2002, The Journal of Immunology.

[4]  L. Steinman,et al.  Multiple sclerosis: deeper understanding of its pathogenesis reveals new targets for therapy. , 2002, Annual review of neuroscience.

[5]  I. Cohen,et al.  β-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial , 2001, The Lancet.

[6]  H. Weiner,et al.  Induction and mechanism of action of transforming growth factor‐β‐secreting Th3 regulatory cells , 2001, Immunological reviews.

[7]  Sayuri Yamazaki,et al.  Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance , 2001, Immunological reviews.

[8]  Roland Martin,et al.  Antigen-specific immunomodulation via altered peptide ligands , 2001, Journal of Molecular Medicine.

[9]  H. Weiner,et al.  Oral administration of insulin to neonates suppresses spontaneous and cyclophosphamide induced diabetes in the NOD mouse. , 2001, Journal of autoimmunity.

[10]  I. Cohen,et al.  Beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial. , 2001, Lancet.

[11]  A. Evans,et al.  Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial , 2000, Nature Medicine.

[12]  J. Frank,et al.  Encephalitogenic potential of the myelin basic protein peptide (amino acids 83–99) in multiple sclerosis: Results of a phase II clinical trial with an altered peptide ligand , 2000, Nature Medicine.

[13]  C. Boitard,et al.  Oral insulin administration and residual (β-cell function in recent-onset type 1 diabetes: a multicentre randomised controlled trial , 2000, The Lancet.

[14]  I. Cohen,et al.  Discrimination and dialogue in the immune system. , 2000, Seminars in immunology.

[15]  H Atlan,et al.  T cell proliferative responses of type 1 diabetes patients and healthy individuals to human hsp60 and its peptides. , 1999, Journal of autoimmunity.

[16]  I. Cohen,et al.  The pathogenicity of islet‐infiltrating lymphocytes in the non‐obese diabetic (NOD) mouse , 1999, Clinical and experimental immunology.

[17]  M. Eisenstein,et al.  The peptide-binding strategy of the MHC class II I-A molecules. , 1998, Immunology today.

[18]  Irun R. Cohen,et al.  Islet T Cells Secreting IFN-γ in NOD Mouse Diabetes: Arrest by p277 Peptide Treatment , 1998 .

[19]  I. Cohen,et al.  Islet T cells secreting IFN-gamma in NOD mouse diabetes: arrest by p277 peptide treatment. , 1998, Journal of autoimmunity.

[20]  I. Cohen,et al.  Biochemical characterization of the human diabetes‐associated HLA‐DQ8 allelic product: Similarity to the major histocompatibility complex class II I‐Ag7 protein of non‐obese diabetic mice , 1997, European journal of immunology.

[21]  Irun R Cohen,et al.  Hsp60 Peptide Therapy of NOD Mouse Diabetes Induces a Th2 Cytokine Burst and Downregulates Autoimmunity to Various β-Cell Antigens , 1997, Diabetes.

[22]  M Eisenstein,et al.  Molecular characterization of the diabetes-associated mouse MHC class II protein, I-Ag7. , 1997, International immunology.

[23]  I. Cohen,et al.  The hsp60 Peptide p277 Arrests the Autoimmune Diabetes Induced by the Toxin Streptozotocin , 1996, Diabetes.

[24]  I. Cohen,et al.  NOD mouse diabetes: the ubiquitous mouse hsp60 is a beta-cell target antigen of autoimmune T cells. , 1996, Journal of autoimmunity.

[25]  I. Cohen,et al.  A role of Hsp60 in autoimmune diabetes: analysis in a transgenic model. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[26]  I. Cohen.  Treatment of autoimmune disease: to activate or to deactivate? , 1995, Chemical immunology.

[27]  I. Cohen,et al.  Autoimmune Diabetes Induced by the β-cell Toxin STZ: Immunity to the 60-kDa Heat Shock Protein and to Insulin , 1994, Diabetes.

[28]  I. Cohen,et al.  Peptide therapy for diabetes in NOD mice , 1994, The Lancet.

[29]  M. A. Bowman,et al.  Prevention of diabetes in the NOD mouse: implications for therapeutic intervention in human disease. , 1994, Immunology today.

[30]  I. Cohen.  The cognitive paradigm and the immunological homunculus. , 1992, Immunology today.

[31]  I. Cohen,et al.  The cognitive principle challenges clonal selection. , 1992, Immunology today.

[32]  I. Cohen,et al.  Vaccination against autoimmune mouse diabetes with a T-cell epitope of the human 65-kDa heat shock protein. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[33]  I. Cohen,et al.  Autoimmunity, microbial immunity and the immunological homunculus. , 1991, Immunology today.

[34]  I. Cohen,et al.  Insulin-Mimicking Anti-Idiotypic Antibodies in Development of Spontaneous Autoimmune Diabetes in BB/E Rats , 1990, Diabetes.

[35]  C. Boitard,et al.  Limited Duration of Remission of Insulin Dependency in Children With Recent Overt Type I Diabetes Treated With Low-Dose Cyclosporin , 1990, Diabetes.

[36]  S. Baekkeskov,et al.  Identification of the 64K autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase , 1990, Nature.

[37]  I. Cohen,et al.  Induction and therapy of autoimmune diabetes in the non-obese diabetic (NOD/Lt) mouse by a 65-kDa heat shock protein. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[38]  S. Baekkeskov,et al.  Cellular and subcellular localization of an Mr 64,000 protein autoantigen in insulin-dependent diabetes. , 1990, The Journal of biological chemistry.

[39]  S. Baekkeskov,et al.  Identification of the 64K autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase , 1990, Nature.

[40]  I. Cohen,et al.  Control of experimental autoimmune encephalomyelitis by T cells responding to activated T cells. , 1989, Science.

[41]  M. Mihatsch,et al.  Factors associated with early remission of type I diabetes in children treated with cyclosporine. , 1988, The New England journal of medicine.

[42]  I. Cohen,et al.  Anti-idiotypic network induced by T cell vaccination against experimental autoimmune encephalomyelitis. , 1988, Science.

[43]  I. Cohen,et al.  Cloning of the mycobacterial epitope recognized by T lymphocytes in adjuvant arthritis , 1988, Nature.

[44]  D. Monos,et al.  Insulin dependent diabetes mellitus as an autoimmune disease. , 1988, In vivo.

[45]  H. Kolb,et al.  Mouse models of insulin dependent diabetes: low-dose streptozocin-induced diabetes and nonobese diabetic (NOD) mice. , 1987, Diabetes/metabolism reviews.

[46]  I. Cohen,et al.  Therapeutic vaccination against adjuvant arthritis using autoimmune T cells treated with hydrostatic pressure. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[47]  I. Cohen,et al.  Arthritis induced by a T-lymphocyte clone that responds to Mycobacterium tuberculosis and to cartilage proteoglycans. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[48]  I. Cohen,et al.  Mouse antibodies to the insulin receptor developing spontaneously as anti-idiotypes. I. Characterization of the antibodies. , 1984, The Journal of biological chemistry.

[49]  I. Cohen,et al.  Mouse antibodies to the insulin receptor developing spontaneously as anti-idiotypes. II. Effects on glucose homeostasis and the insulin receptor. , 1984, The Journal of biological chemistry.

[50]  I. Cohen,et al.  Arthritis induced in rats by cloned T lymphocytes responsive to mycobacteria but not to collagen type II. , 1984, The Journal of clinical investigation.

[51]  B. M. Jongh,et al.  Autoantibodies to the insulin receptor in juvenile onset insulin-dependent diabetes , 1983, Nature.

[52]  I. Cohen,et al.  Vaccination against autoimmune encephalomyelitis with T-lymphocite line cells reactive against myelin basic protein , 1981, Nature.

[53]  I. Cohen,et al.  The rapid isolation of clonable antigen‐specific T lymphocyte lines capable of mediating autoimmune encephalomyelitis , 1981, European journal of immunology.

[54]  V. Lev-Ram,et al.  Immune response genes have a variable influence on the selection of antigenic foreign and self determinants of insulin. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[55]  I. Cohen,et al.  Non-Type Specific Resistance to Group A Streptococci in Germ Free and Conventional Mice.∗ , 1963, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.